Montgomery County’s Business Innovation Network is pleased to announce that Rockville’s own ReveraGen BioPharma, Inc., a Rockville Innovation Center tenant, granted an option to in-license vamorolone to Swiss company Actelion Ltd. This agreement marks the first tech transfer out of Children’s National Medical Center. Prior to moving to the Rockville Innovation Center, ReveraGen made their home at the Shady Grove Innovation Center.
Actelion Ltd and ReveraGen BioPharma, Inc., announced via press release that they entered into an agreement on November 3, 2016. By this agreement, Actelion has obtained an exclusive option to in-license ReveraGen’s lead compound vamorolone for the treatment of Duchenne Muscular Dystrophy at two different stages in its development.